Granzyme A amplifies human neutrophil pyroptosis
This study identifies Granzyme A as a non-canonical, caspase-independent amplifier of human neutrophil pyroptosis that directly cleaves gasdermins without generating canonical pore-forming fragments, suggesting its selective inhibition could modulate neutrophil-driven inflammatory responses.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The human body maintains a delicate balance between fighting infection and avoiding self-destruction, a task managed in large part by the immune system's first responders: white blood cells called neutrophils. These cells are the rapid reaction force, rushing to sites of injury or infection to engulf and destroy invading bacteria. However, their power is double-edged. If they live too long, they can cause chronic inflammation and damage healthy tissue; if they die too quickly or in the wrong way, the body loses its defense. To manage this, neutrophils have several ways to end their own lives. Some die quietly, allowing the body to recycle them without causing a fuss. Others die explosively, bursting open to release their contents and sound an alarm to the rest of the immune system. This loud, inflammatory form of death is known as pyroptosis. For years, scientists have known that neutrophils contain a dense storage of enzymes, like tiny biological weapons, waiting to be released. But one specific enzyme, granzyme A, has been a mystery. While it is well-known for its role in killing infected cells from the outside, its presence and purpose inside the neutrophil itself have been debated and unclear.
A team of researchers set out to solve this puzzle by looking directly at human neutrophils to see if granzyme A is actually there, what it is doing, and how it influences the cell's decision to die. They began by confirming that granzyme A is indeed stored inside the primary granules of human neutrophils, sitting alongside other powerful enzymes in a state of readiness. Crucially, they found that this enzyme is not just a dormant protein waiting to be used; it is chemically active, capable of cutting other proteins the moment it is released from its storage container. To test what happens when this enzyme is unleashed, the scientists used a specialized chemical tool that acts like a precise lock, disabling granzyme A without affecting the other enzymes in the cell. They then triggered the neutrophils to undergo pyroptosis, a violent form of cell death, using a substance that disrupts the cell's internal chemistry.
The results showed that when granzyme A was disabled, the neutrophils did not die as quickly. The chemical lock delayed the explosion, slowing down the process of the cell bursting open. This suggested that granzyme A acts as an amplifier, speeding up the inflammatory death of the cell once the process has already started. The researchers also discovered that this enzyme works independently of the usual cellular machinery that controls cell death, which relies on a different set of proteins called caspases. Instead, granzyme A seems to take a shortcut, directly attacking the structural proteins of the cell. Specifically, the team found that granzyme A can cut two key proteins, gasdermin D and gasdermin E, which are responsible for punching holes in the cell membrane. However, unlike other enzymes that cut these proteins to activate them, granzyme A cuts them in a way that suggests it might be dismantling them or altering their function rather than simply turning them on.
The study also revealed that this mechanism is specific to humans. When the researchers tested the same process in mouse neutrophils, they found that granzyme A was barely present and did not play a significant role in their cell death. This highlights a fundamental difference between human and mouse biology, reminding scientists that findings in mice do not always translate directly to people. Furthermore, the researchers observed that granzyme A remains trapped inside the cell during the early stages of death, only leaking out once the cell has completely fallen apart. This timing indicates that the enzyme is working from the inside, helping to drive the cell toward its explosive end rather than acting as an external signal.
By blocking granzyme A, the scientists also noticed a reduction in the production of reactive oxygen species, which are highly reactive molecules that can damage cells and fuel inflammation. This suggests that granzyme A is part of a chain reaction that leads to oxidative stress, further accelerating the cell's demise. The team confirmed these findings using a second method, creating neutrophil-like cells from human stem cells in a lab, which showed the same behavior. This consistency across different human models strengthens the conclusion that granzyme A is a genuine regulator of how human neutrophils die.
The work does not suggest that granzyme A is the sole cause of this cell death, but rather a critical accelerator. When the cell is stressed, granzyme A is released from its storage, moves into the main part of the cell, and helps execute the final stages of the inflammatory death program. The researchers also noted that while granzyme A cuts the proteins that form holes in the cell membrane, it does not create the standard, functional holes that other enzymes make. This implies that granzyme A might be modifying these proteins to change how the cell dies, perhaps making the process more efficient or altering the signals sent to the immune system.
Ultimately, this research clarifies a long-standing question about the inner workings of human immune cells. It establishes that granzyme A is a key player in the inflammatory death of neutrophils, acting as a catalyst that speeds up the process and increases the release of damaging molecules. By identifying this specific role, the study opens the door to new ways of thinking about how to control inflammation. If scientists can selectively block granzyme A, they might be able to slow down the destructive cycle of inflammation in diseases where neutrophils are overactive, without shutting down the entire immune system. The findings provide a clearer map of the molecular events that occur when a human neutrophil decides to sacrifice itself, revealing a specific enzyme that turns up the volume on the body's inflammatory alarm.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.